These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 27023688)

  • 1. Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program.
    Keast SL; Owora A; Nesser N; Farmer K
    J Manag Care Spec Pharm; 2016 Apr; 22(4):347-56. PubMed ID: 27023688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incremental Effect of the Addition of Prescriber Restrictions on a State Medicaid's Pharmacy-Only Patient Review and Restriction Program.
    Keast SL; Pham T; Teel A; Nesser NJ
    J Manag Care Spec Pharm; 2017 Aug; 23(8):875-883. PubMed ID: 28737989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients.
    Cicero TJ; Mendoza M; Cattaneo M; Dart RC; Mardekian J; Polson M; Roland CL; Schnoll SH; Webster LR; Park PW
    Postgrad Med; 2019 Apr; 131(3):225-229. PubMed ID: 30794760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of prescription opioids with abuse-deterrent technology to address opioid abuse.
    Michna E; Kirson NY; Shei A; Birnbaum HG; Ben-Joseph R
    Curr Med Res Opin; 2014 Aug; 30(8):1589-98. PubMed ID: 24738694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamper-resistant opioid formulations in the treatment of acute pain.
    Passik SD
    Adv Ther; 2014 Mar; 31(3):264-75. PubMed ID: 24526323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid Use for Pain Management After Implementation of a Medicaid Short-Acting Opioid Quantity Limit.
    Riggs CS; Billups SJ; Flores S; Patel RJ; Heilmann RM; Milchak JL
    J Manag Care Spec Pharm; 2017 Mar; 23(3):346-354. PubMed ID: 28230448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using prescription monitoring program data to characterize out-of-pocket payments for opioid prescriptions in a state Medicaid program.
    Hartung DM; Ahmed SM; Middleton L; Van Otterloo J; Zhang K; Keast S; Kim H; Johnston K; Deyo RA
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1053-1060. PubMed ID: 28722211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone.
    Peacock A; Degenhardt L; Larance B; Cama E; Lintzeris N; Ali R; Bruno R
    Pharmacoepidemiol Drug Saf; 2015 Dec; 24(12):1321-33. PubMed ID: 26419615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the Direct Costs of Outpatient Opioid Prescriptions: A Retrospective Analysis of Data from the Rhode Island Prescription Drug Monitoring Program.
    Aroke H; Buchanan A; Wen X; Ragosta P; Koziol J; Kogut S
    J Manag Care Spec Pharm; 2018 Mar; 24(3):214-224. PubMed ID: 29485950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.
    Gasior M; Bond M; Malamut R
    Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
    Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
    Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
    Yenikomshian MA; White AG; Carson ME; Garrison LP; Oderda GM; Biskupiak JE; Hlavacek PR; Roland CL
    J Opioid Manag; 2017; 13(5):291-301. PubMed ID: 29199395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use?
    Lourenço LM; Matthews M; Jamison RN
    Expert Opin Drug Deliv; 2013 Feb; 10(2):229-40. PubMed ID: 23252692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of an opioid management initiative by a state Medicaid program.
    Garcia MM; Angelini MC; Thomas T; Lenz K; Jeffrey P
    J Manag Care Spec Pharm; 2014 May; 20(5):447-54. PubMed ID: 24761816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy.
    Bucher Bartelson B; Le Lait MC; Green JL; Cepeda MS; Coplan PM; Maziere JY; Wedin GP; Dart RC
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1061-1070. PubMed ID: 28758289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
    Webster LR; Markman J; Cone EJ; Niebler G
    Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study.
    Larance B; Dobbins T; Peacock A; Ali R; Bruno R; Lintzeris N; Farrell M; Degenhardt L
    Lancet Psychiatry; 2018 Feb; 5(2):155-166. PubMed ID: 29336948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of a Federal Controlled Substance Act Schedule Change on Hydrocodone Combination Products Claims in a Medicaid Population.
    Tran S; Lavitas P; Stevens K; Greenwood BC; Clements K; Alper CJ; Lenz K; Price M; Hydery T; Arnold JL; Takeshita M; Bacon R; Peristere JP; Jeffrey PL
    J Manag Care Spec Pharm; 2017 May; 23(5):532-539. PubMed ID: 28448772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Chronic Multiclass Psychotropic Polypharmacy and Psychotherapy in Foster Care Youth in a State Medicaid Population.
    Keast SL; Tidmore LM; Shropshire D; Nesser N; Lambert TL
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1340-1348. PubMed ID: 31778625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid.
    Pham TT; Keast SL; Farmer KC; Thompson DM; Rathbun RC; Nesser NJ; Holderread BP; Skrepnek GH
    J Manag Care Spec Pharm; 2018 Jul; 24(7):664-676. PubMed ID: 29952711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.